Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1

Autor: Ciruelos, Eva Maria, Rugo, Hope S, Mayer, Ingrid A, Levy, Christelle, Forget, Frédéric, Delgado Mingorance, Juan Ignacio, Safra, Tamar, Masuda, Norikazu, Park, Yeon Hee, Juric, Dejan, Conte, Pierfranco, Campone, Mario, Loibl, Sibylle, Iwata, Hiroji, Zhou, Xiaolei, Park, Jinhee, Ridolfi, Antonia, Lorenzo, Ines, André, Fabrice

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 18

PurposeIn the phase III SOLAR-1 trial (NCT02437318), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-kina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::2a0a4dc85008cb76acc40523157b19b2
https://escholarship.org/uc/item/31f7j2v6

Patient-Reported Outcomes in Patients With -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.

Autor: Ciruelos, Eva Maria, Rugo, Hope S, Mayer, Ingrid A, Levy, Christelle, Forget, Frédéric, Delgado Mingorance, Juan Ignacio, Safra, Tamar, Masuda, Norikazu, Park, Yeon Hee, Juric, Dejan, Conte, Pierfranco, Campone, Mario, Loibl, Sibylle, Iwata, Hiroji, Zhou, Xiaolei, Park, Jinhee, Ridolfi, Antonia, Lorenzo, Ines, André, Fabrice

Publikováno v: Journal of Clinical Oncology; 6/20/2021, Vol. 39 Issue 18, p2005-2015, 11p

The importance of early identification of infusion-related reactions to monoclonal antibodies.

Autor: Cáceres, Macarena C, Guerrero-Martín, Jorge, Pérez-Civantos, Demetrio, Palomo-López, Patricia, Delgado-Mingorance, Juan Ignacio, Durán-Gómez, Noelia

Publikováno v: Therapeutics & Clinical Risk Management; Aug2019, Vol. 15, p965-977, 13p

Patient-Reported Outcomes in Patients With PIK3CA -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.

Autor: Ciruelos EM; Department of Medical Oncology, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain., Rugo HS; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Mayer IA; Division of Hematology/Oncology, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN., Levy C; Responsable de l'Institut Normand du Sein, Centre François Baclesse, Caen, France., Forget F; Oncologie CHA, Hôpital de Libramont, Vivalia, Libramont-Chevigny, Belgium., Delgado Mingorance JI; Oncology Department, University Hospital of Badajoz, Servicio Extremeño de Salud, Badajoz, Spain, and Hospital Infanta Cristina, Badajoz, Spain., Safra T; Medical Oncology and Radiotherapy, Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Masuda N; Department of Surgery and Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Park YH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Juric D; Departments of Hematology/Oncology and Medicine, Massachusetts General Hospital, Boston, MA., Conte P; Dipartimento Di Scienze Chirurgiche Oncologiche e Gastroenterologiche, Università di Padova and Oncologia Medica 2, Istituto Oncologico Veneto IRCCS, Padova, Italy., Campone M; Institut de Cancérologie de l'Ouest, Angers, France., Loibl S; German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany.; Center for Haematology and Oncology, Bethanien Hospital, Frankfurt, Germany., Iwata H; Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan., Zhou X; RTI Health Solutions, Research Triangle Park, NC., Park J; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Ridolfi A; Global Medical Affairs Biostatistics, Novartis Pharma S.A.S., Rueil-Malmaison, France., Lorenzo I; Novartis Oncology, Madrid, Spain., André F; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Jun 20; Vol. 39 (18), pp. 2005-2015. Date of Electronic Publication: 2021 Mar 29.